Adicet Bio Files 8-K Report
Ticker: ACET · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1720580
| Field | Detail |
|---|---|
| Company | Adicet Bio, Inc. (ACET) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Adicet Bio filed an 8-K, likely containing routine disclosures. Keep an eye out for details.
AI Summary
On July 8, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Adicet Bio is providing updates or disclosures required by the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events, indicating low immediate risk.
Key Players & Entities
- Adicet Bio, Inc. (company) — Registrant
- resTORbio, Inc. (company) — Former company name
- July 08, 2024 (date) — Date of earliest event reported
- 001-38359 (other) — SEC File Number
- 81-3305277 (other) — IRS Employer Identification No.
FAQ
What specific information is being disclosed in this 8-K filing?
The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', suggesting it contains disclosures related to these areas, though specific details are not in the provided text.
When was the earliest event reported in this filing?
The earliest event reported is dated July 08, 2024.
What is Adicet Bio, Inc.'s former company name?
Adicet Bio, Inc.'s former company name was resTORbio, Inc.
What is Adicet Bio, Inc.'s principal executive office address?
The principal executive offices are located at 131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116.
What is the SEC file number for Adicet Bio, Inc.?
The SEC file number for Adicet Bio, Inc. is 001-38359.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-08 07:01:37
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma
Filing Documents
- acet-20240708.htm (8-K) — 41KB
- acet-ex99_1.htm (EX-99.1) — 15KB
- 0000950170-24-081943.txt ( ) — 170KB
- acet-20240708.xsd (EX-101.SCH) — 24KB
- acet-20240708_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 8, 2024, Adicet Bio, Inc. issued a press release titled "Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Exhibits
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on July 8, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ADICET BIO, INC. Date: July 8, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer